By Andy Batts : Genetic diagnostics lab GeneDx filed eleven petitions to invalidate patent claims held by Myriad Genetics (NASDAQ: MYGN ), according to a recent report . This is the first move against Myriad's patents to take advantage of
Strong cash flow generation has enabled the firm to begin to return cash to shareholders in the form of share repurchases. Myriad Genetics develops genetic diagnostic products, and is best known for its BRACAnalysis test, which assesses a woman’s risk of
REED +13% . EVK +13% . OTCQB:AMTX +12% . ASPN +12% . Top 10 Losers: SEAS -32% . KING -23% . NLST -15% . INPH -14% . RIGL -12% . KWK -12% . SIGA -11% . EVRY -12% . MYGN -10% . FATE -10% . Post your comment!
Myriad Genetics reported fourth-quarter earnings Tuesday that were largely in line with our expectations as growth saw headwinds from revised
Myriad Genetics ( MYGN -3.3% ) fiscal Q4 and full year results : Fiscal Q4 Revenues: $188.8M (+8.4%); Operating Income: $53.3M
Aug 12 (Reuters) - Molecular diagnostics company Myriad Genetics Inc forecast a lower-than-expected full-year adjusted profit, hurt partly by the termination of its contract with affordable health insurance provider Horizon Blue Cross in May.
Top gainers, as of 5:15 p.m.: SRPT +5.9% . REXX +5.1% . PE +4.6% . MHR +4.3% . NPSP +4.3% . Top losers, as of 5:15 p.m.: KING -21.1% . ARWR -11.9% . QNST -9.8% . CREE -6.3% . MYGN -5.1% . Post your comment!
CHMI , CREE , EPAY , FMI , FOSL , FTD , HMIN , JDSU , JKHY , KING , MYGN , OTC:OPWR , PE , PRSS , SYNC , TCX , URS , VSAT Post your comment!
confident about right now? I discussed Myriad Genetics in January, and I still really like ..... portfolios for more than a decade. Like Myriad Genetics , its share price has been somewhat ..... 0.00 0.00 0.00 1.32 0.00 Myriad Genetics 3.18 1.90 3.56 4.02 0.00
Myriad Genetics reported third-quarter earnings on Tuesday that were largely in line with our expectations, as private-payer pricing remained